FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320888937> ?p ?o ?g. }

• W4320888937 endingPage "217" @default.
• W4320888937 startingPage "209" @default.
• W4320888937 abstract "Background Intranasal formulations can provide treatment options for people with migraine in whom oral drugs are ineffective, slow-acting, or intolerable because of nausea and vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. This phase 3 trial aimed to compare the efficacy, tolerability, safety, and timecourse of response for zavegepant nasal spray with placebo in the acute treatment of migraine. Methods This double-blind, randomised, placebo-controlled, multicentre phase 3 trial, conducted at 90 academic medical centres, headache clinics, and independent research facilities in the USA, recruited adults (aged ≥18 years) with a history of two to eight moderate or severe migraine attacks per month. Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use or non-use of preventive medication. Study centre personnel entered eligible participants into the study using an interactive web response system that was operated and managed by an independent contract research organisation. All participants, investigators, and the funder were masked to group assignment. The coprimary endpoints, freedom from pain and freedom from the most bothersome symptom at 2 h after the treatment dose, were assessed in all randomly assigned participants who took the study medication, had a migraine attack of moderate or severe pain intensity at baseline, and provided at least one evaluable post-baseline efficacy datapoint. Safety was analysed in all randomly assigned participants who received at least one dose. The study is registered with ClinicalTrials.gov, number NCT04571060, and is closed to accrual. Findings Between Oct 27, 2020, and Aug 20, 2021, 1978 participants were recruited and assessed for eligibility. 1405 participants were eligible (703 were assigned to zavegepant and 702 to placebo), and 1269 were included in the efficacy analysis set (623 in the zavegepant group and 646 in the placebo group). 2 h after the treatment dose, more participants in the zavegepant group than in the placebo group had pain freedom (147 [24%] of 623 participants vs 96 [15%] of 646 participants, risk difference 8·8 percentage points, 95% CI 4·5–13·1; p<0·0001) and freedom from their most bothersome symptom (247 [40%] vs 201 [31%], risk difference 8·7 percentage points, 3·4–13·9; p=0·0012). The most common adverse events in either treatment group (≥2%) were dysgeusia (129 [21%] of 629 in the zavegepant group vs 31 [5%] of 653 in the placebo group), nasal discomfort (23 [4%] vs five [1%]), and nausea (20 [3%] vs seven [1%]). No signal of hepatotoxicity due to zavegepant was identified. Interpretation Zavegepant 10 mg nasal spray was efficacious in the acute treatment of migraine, with favourable tolerability and safety profiles. Additional trials are needed to establish the long-term safety and consistency of effect across attacks. Funding Biohaven Pharmaceuticals." @default.
• W4320888937 created "2023-02-16" @default.
• W4320888937 creator A5000448269 @default.
• W4320888937 creator A5004525209 @default.
• W4320888937 creator A5015085688 @default.
• W4320888937 creator A5029703470 @default.
• W4320888937 creator A5054020423 @default.
• W4320888937 creator A5060859207 @default.
• W4320888937 creator A5069362203 @default.
• W4320888937 creator A5083474879 @default.
• W4320888937 creator A5086458638 @default.
• W4320888937 date "2023-03-01" @default.
• W4320888937 modified "2023-10-17" @default.
• W4320888937 title "Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial" @default.
• W4320888937 cites W1984607232 @default.
• W4320888937 cites W1992472429 @default.
• W4320888937 cites W2047455969 @default.
• W4320888937 cites W2073955297 @default.
• W4320888937 cites W2083120125 @default.
• W4320888937 cites W2085595272 @default.
• W4320888937 cites W2095583476 @default.
• W4320888937 cites W2126194551 @default.
• W4320888937 cites W2135331807 @default.
• W4320888937 cites W2138814983 @default.
• W4320888937 cites W2154328498 @default.
• W4320888937 cites W2166206304 @default.
• W4320888937 cites W2166530830 @default.
• W4320888937 cites W2277818347 @default.
• W4320888937 cites W2752113038 @default.
• W4320888937 cites W2801085490 @default.
• W4320888937 cites W2895868360 @default.
• W4320888937 cites W2897545213 @default.
• W4320888937 cites W3094395521 @default.
• W4320888937 cites W3119146323 @default.
• W4320888937 cites W3150487324 @default.
• W4320888937 cites W4200491979 @default.
• W4320888937 cites W4282045881 @default.
• W4320888937 cites W4283277701 @default.
• W4320888937 cites W4306164358 @default.
• W4320888937 cites W58525860 @default.
• W4320888937 doi "https://doi.org/10.1016/s1474-4422(22)00517-8" @default.
• W4320888937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36804093" @default.
• W4320888937 hasPublicationYear "2023" @default.
• W4320888937 type Work @default.
• W4320888937 citedByCount "19" @default.
• W4320888937 countsByYear W43208889372023 @default.
• W4320888937 crossrefType "journal-article" @default.
• W4320888937 hasAuthorship W4320888937A5000448269 @default.
• W4320888937 hasAuthorship W4320888937A5004525209 @default.
• W4320888937 hasAuthorship W4320888937A5015085688 @default.
• W4320888937 hasAuthorship W4320888937A5029703470 @default.
• W4320888937 hasAuthorship W4320888937A5054020423 @default.
• W4320888937 hasAuthorship W4320888937A5060859207 @default.
• W4320888937 hasAuthorship W4320888937A5069362203 @default.
• W4320888937 hasAuthorship W4320888937A5083474879 @default.
• W4320888937 hasAuthorship W4320888937A5086458638 @default.
• W4320888937 hasConcept C126322002 @default.
• W4320888937 hasConcept C142724271 @default.
• W4320888937 hasConcept C168563851 @default.
• W4320888937 hasConcept C1862650 @default.
• W4320888937 hasConcept C197934379 @default.
• W4320888937 hasConcept C204787440 @default.
• W4320888937 hasConcept C27081682 @default.
• W4320888937 hasConcept C2778375690 @default.
• W4320888937 hasConcept C2778541695 @default.
• W4320888937 hasConcept C2780580376 @default.
• W4320888937 hasConcept C2780973058 @default.
• W4320888937 hasConcept C42219234 @default.
• W4320888937 hasConcept C535046627 @default.
• W4320888937 hasConcept C71924100 @default.
• W4320888937 hasConcept C85663871 @default.
• W4320888937 hasConcept C98274493 @default.
• W4320888937 hasConceptScore W4320888937C126322002 @default.
• W4320888937 hasConceptScore W4320888937C142724271 @default.
• W4320888937 hasConceptScore W4320888937C168563851 @default.
• W4320888937 hasConceptScore W4320888937C1862650 @default.
• W4320888937 hasConceptScore W4320888937C197934379 @default.
• W4320888937 hasConceptScore W4320888937C204787440 @default.
• W4320888937 hasConceptScore W4320888937C27081682 @default.
• W4320888937 hasConceptScore W4320888937C2778375690 @default.
• W4320888937 hasConceptScore W4320888937C2778541695 @default.
• W4320888937 hasConceptScore W4320888937C2780580376 @default.
• W4320888937 hasConceptScore W4320888937C2780973058 @default.
• W4320888937 hasConceptScore W4320888937C42219234 @default.
• W4320888937 hasConceptScore W4320888937C535046627 @default.
• W4320888937 hasConceptScore W4320888937C71924100 @default.
• W4320888937 hasConceptScore W4320888937C85663871 @default.
• W4320888937 hasConceptScore W4320888937C98274493 @default.
• W4320888937 hasIssue "3" @default.
• W4320888937 hasLocation W43208889371 @default.
• W4320888937 hasLocation W43208889372 @default.
• W4320888937 hasOpenAccess W4320888937 @default.
• W4320888937 hasPrimaryLocation W43208889371 @default.
• W4320888937 hasRelatedWork W1550475500 @default.
• W4320888937 hasRelatedWork W17603917 @default.
• W4320888937 hasRelatedWork W2022556905 @default.
• W4320888937 hasRelatedWork W2051283521 @default.
• W4320888937 hasRelatedWork W2107697672 @default.

• next